Medicare IPI Model Could Import Benefit Of Biosimilar Competition, Azar Suggests
Executive Summary
HHS secretary notes Medicare Part B International Pricing Index could ‘harness’ biosimilar price competition seen abroad for US market, where follow-ons have not been able to significantly impact pricing.
You may also be interested in...
Big Pharma Defuses Drug Pricing Landmines On Capitol Hill
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
Big Pharma Defuses Drug Pricing Landmines On Capitol Hill
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.
Democratic Oversight And Trump’s Rx Price Blueprint: Three Possible Routes
House Democrats and the Trump Administration share an interest in taking on high drug prices. They probably won’t cooperate – but will the House actively block administrative changes?